Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01113619 · ClinicalTrials.gov registry record · Phase 2
Effectiveness, Safety and Tolerability Study of RP-G28 for Symptoms Associated With Lactose Intolerance
A Phase 2 study of Lactose Intolerance, sponsored by Ritter Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
- 2
- Study locations
NCT01113619 is a Phase 2 study of Lactose Intolerance that has completed, run by Ritter Pharmaceuticals. The registered enrollment target is 61 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT01113619, a Phase 2 study of Lactose Intolerance, has completed, sponsored by Ritter Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase 2 study designed to assess the ability of RP-G28 to improve lactose digestion and tolerance.
Conditions Studied
Interventions
- DRUG RP-G28 or placebo
Study Locations (2)
Hawaii
- Covance, Inc. - Honolulu - Honolulu
Texas
- Covance, Inc. - Dallas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2011-04 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01113619
The ClinicalTrials.gov registry entry for NCT01113619 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ritter Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lactose Intolerance appearing as the primary indexed condition, and to 1 intervention - of which RP-G28 or placebo is the first listed.
NCT01113619 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Hawaii, Texas.
Frequently Asked Questions
What is clinical trial NCT01113619 about?
NCT01113619 is a clinical study titled "Effectiveness, Safety and Tolerability Study of RP-G28 for Symptoms Associated With Lactose Intolerance". This is a Phase 2 study designed to assess the ability of RP-G28 to improve lactose digestion and tolerance.
What is the current status of trial NCT01113619?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2011-04. Estimated completion is 2011-12.
What conditions does trial NCT01113619 study?
This clinical trial studies the following conditions: Lactose Intolerance.
What interventions are being tested in trial NCT01113619?
The interventions under investigation include: RP-G28 or placebo (DRUG).
Who is sponsoring clinical trial NCT01113619?
This trial is sponsored by Ritter Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01113619 being conducted?
This trial has 2 study locations across Hawaii, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.